Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by apatch808on May 31, 2018 4:44pm

142 Views

Post# 28107980

Phase II Approval/Commencement

I think the assumption is a Phase II will (eventually) be approved. The question is when will approval occur and when will the Phase II commence. I am guessing Q2/3 2018 for approval, and Q1/2 2019 for actually starting. Is this what you all are thinking, or am I off by a lot?

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?